

TFW

1617

PATENT
Customer No. 22,852
Attorney Docket No. 02481.1702

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Bernward SCHÖLKENS et al.) Group Art Unit: 1617
)
Application No.: 09/645,556) Examiner: J. Kim
)
Filed: August 25, 2000) Confirmation No.: 3278
)
For: PHARMACEUTICAL)
FORMULATIONS AND USE)
THEREOF IN THE PREVENTION)
OF STROKE, DIABETES AND/OR)
CONGESTIVE HEART FAILURE)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

04/10/2006 HALI11 00000114 09645556

01 FC:1806

180.00 DP

Document Nos. 1-4 cited in the IDS Form PTO/SB/08 are being cited for the first time in this application. Document Nos. 5-19 have been cited earlier. Errors were found in the earlier citations to document Nos. 5-19 and, as a result, the documents are being cited again to correct those errors. The undersigned apologizes for any inconvenience associated with the re-submission of these documents.

With regard to the non-English language document Deng et al., an English language abstract appears on the first page of the document.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 7, 2006

By: 
Steven J. Scott
Reg. No. 43,911

APR 07 2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	09/645,556
Filing Date	August 25, 2000
First Named Inventor	Bernward SCHÖLKENS
Art Unit	1617
Examiner Name	Kim, Jennifer M.
Attorney Docket Number	02481.1702

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
	1	Braunwald, Ed., "Heart Disease: A Textbook of Cardiovascular Medicine," vol. 1, Chapter 15, "Clinical Aspects of Heart Failure: High-Output Heart Failure; Pulmonary Edema," W.B. Saunders Company, pp. 445-470 (1997)	
	2	Pitt et al., "The QUinapril Ischemic Event Trial (QUIET): Evaluation of Chronic ACE Inhibitor Therapy in Patients With Ischemic Heart Disease and Preserved Left Ventricular Function," The American Journal of Cardiology, vol. 87, pp. 1058-1063 (2001)	
	3	Schulz et al., "Cardiovascular Therapy: Evidence-based Medicine -Questions and Answers-," Table of Contents and Chapter F, "Post-myocardial infarction with poor LV function," medpharm GmbH Scientific Publishers, pp. 7-14 and 171-183 (2001)	
	4	The EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators, "Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study), The LANCET, vol. 362, pp. 782-788 (2003)	
	5	Abstract From the 65 th Scientific Sessions, Circulation, vol. 86 (4 Suppl. 1), p. I-53, Abstracts 0207-0210 (1992)	
	6	Anderson et al., "Therapeutic Advantage of Converting Enzyme Inhibitors in Arresting Progressive Renal Disease Associated with Systemic Hypertension in the Rat," J. Clin. Invest., vol. 77, pp. 1993-2000 (1986)	
	7	Brown et al., "Angiotensin-Converting Enzyme Inhibitors," Circulation, vol. 97, pp. 1411-1420 (1998)	
	8	Cambien et al., "Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction," Nature, vol. 359, pp. 641-644 (1992)	
	9	Deng et al., "Proinflammatorische Zytokine und kardiale Pumpfunktion," Z. Kardiol, vol. 86, pp. 788-802 (1997)	Abstract
	10	FDA Orange Book Active Ingredient Detail Record Search, printed on June 8, 2001	
	11	Editorial, "Angiotensin II: Hemodynamic Regulator or Growth Factor?," J. Mol Cell Cardiol, vol. 22, pp. 739-747 (1990)	
	12	Law, "Lipids and cardiovascular disease," Evidence Based Cardiology, BMJ Books, pp. 191-205 (1998)	
	13	Lee et al., "Effects of perindopril on hypertension and stroke prevention in experimental animals," Can. J. Cardiol., vol. 10 (suppl. D), pp. 33D-36D (1994)	
	14	Ogiku et al., "Prophylactic Effect of Imidapril on Stroke in Stroke-Prone Spontaneously Hypertensive Rats," Stroke, vol. 24, no. 2, pp. 245-252 (1993)	

Complete if Known

Application Number	09/645,556
Filing Date	August 25, 2000
First Named Inventor	Bernward SCHÖLKENS
Art Unit	1617
Examiner Name	Kim, Jennifer M.
Attorney Docket Number	02481.1702

Sheet	2	of	2
-------	---	----	---

[illegible]Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.